Answers are grounded in this paper and cite their sources.
The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic infliximab trough levels remains uncertain, as does whether post-intensification trough and treatment targets should influence this decision.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: